Effect of azithromycin plus rifampin versus amoxicillin alone on eradication and inflammation in the chronic course of Chlamydia pneumoniae pneumonitis in mice

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 6, 2000, Pages 1761-1764

  Bin, Xie Xiao ^a,b   Wolf, Katerina ^a,c   Schaffner, Thomas ^a   Malinverni, Raffaele ^a,d  

^a UNIVERSITY OF BERN   (Switzerland)

^b Stadtspital Triemli Departement fur Innere Medizin Abteilung fur Gastroenterologie   (Switzerland)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d Hopital Pourtales Neuchatelois   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; RIFAMPICIN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; CHLAMYDOPHILA PNEUMONIAE; CHRONIC DISEASE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ERADICATION THERAPY; MALE; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL;

AMOXICILLIN; ANIMALS; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHLAMYDIA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; DRUG THERAPY, COMBINATION; MICE; PNEUMONIA; RIFAMPIN;

EID: 0343362694     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.6.1761-1764.2000     Document Type: Article

References (23)

1. Anderson, J. L., J. B. Muhlestein, J. Carlquist, A. Allen, S. Trehan, C. Nielson, S. Hall, J. Brady, M. Egger, B. Horne, and T. Lim. 1999. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. Circulation 99:1540-1547.
2. Beale, A. S., E. Faulds, S. E. Hurn, J. Tyler, and B. Slocombe. 1991. Comparative activities of amoxycillin, amoxycillin/clavulanic acid and tetracyclinc against Chlamydia trachomatis in cell culture and in an experimental mouse pneumonitis. J. Antimicrob. Chemother. 27:627-638.
3. Beatty, W. L., R. P. Morrison, and G. I. Byrne. 1994. Persistent chlamydiae: from cell culture to a paradigm of chlamydial pathogenesis. Microbiol. Rev. 58:686-699.
4. Bowie, W. R., C. K. Lee, and E. R. Alexander. 1978. Prediction of efficacy of antimicrobial agents in treatment of infections due to Chlamydia trachomatis. J. Infect. Dis. 138:655-659.
5. Bowie, W. R. 1986. In vitro activity of clavulanic acid, amoxicillin, and ticarcillin against Chlamydia trachomatis. Antimicrob. Agents Chemother. 29:713-715.
6. Calleja, C., J. M. Pascussi, J. C. Mani, P. Maurel, and M. J. Vilarem. 1998. The antibiotic rifampicin is a nonsteroidal ligand and activator of the human glucocorticoid receptor. Nat. Med. 4:92-96.
7. Campbell, L. A., M. Perez Melgosa, D. J. Hamilton, C.-C. Kuo, and J. T. Grayston. 1992. Detection of Chlamydia pneumoniae by polymerase chain reaction. J. Clin. Microbiol. 30:434-439.
8. Ehret, J. M., and F. N. Judson. 1988. Susceptibility testing of Chlamydia trachomatis: from eggs to monoclonal antibodies. Antimicrob. Agents Chemother. 32:1295-1299.
9. Furesz, S. 1970. Chemical and biological properties of rifampicin. Antibiot. Chemother. 16:316-351.
10. Gupta, S., E. W. Leatham, D. Carrington, M. A. Mendall, J. C. Kaski, and A. J. Camm. 1997. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 96:404-407.
11. Gurfinkel, E., G. Bozovich, A. Daroca, E. Beck, and B. Mautner. 1997. Randomized trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study. Lancet 350:404-407.
12. Hammerschlag, M. R. 1994. Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae. Antimicrob. Agents Chemother. 38:1873-1878.
13. Jones, R. B., G. L. Ridgway, S. Boulding, and K. L. Hunley. 1983. In vitro activity of rifamycins alone and in combination with other antibiotics against Chlamydia trachomatis. Rev. Infect. Dis. 5(Suppl. 3):556-561.
14. Keshishyan, H., L. Hanna, and E. Jawetz. 1973. Emergence of rifampin-resistance in Chlamydia trachomatis. Nature 244:173-174.
15. Kramer, M. J., R. Cleeland, and E. Grunberg. 1979. Activity of oral amoxicillin, ampicillin, and oxytetracycline against infection with Chlamydia trachomatis in mice. J. Infect. Dis. 139:717-719.
16. Kuo, C. C., and J. T. Grayston. 1988. In vitro drug susceptibility of Chlamydia sp. strain TWAR. Antimicrob. Agents Chemother. 32:257-258.
17. Kuo, C. C., L. A. Jackson, L. A. Campbell, and J. T. Grayston. 1995. Chlamydia pneumoniae (TWAR). Clin. Microbiol. Rev. 8:451-461.
18. Malinverni, R., C. C. Kuo, L. A. Campbell, A. Lee, and J. T. Grayston. 1995. Effects of two antibiotic regimens on the course and persistence of experimental Chlamydia pneumoniae TWAR pneumonitis. Antimicrob. Agents Chemother. 39:45-49.
19. Malinverni, R., C. C. Kuo, L. A. Campbell, and J. T. Grayston. 1995. Reactivation of Chlamydia pneumoniae lung infection in mice by cortisone. J. Infect. Dis. 172:593-594.
20. Masson, N., C. D. Nigel Toseland, and A. S. Beale. 1995. Relevance of Chlamydia pneumoniae murine pneumonitis model to evaluation of antimicrobial agents. Antimicrob. Agents Chemother. 39:1959-1954.
21. Nakata, K., Y. Okazaki, H. Hattori, and S. Nakamura. 1994. Protective effects of sparfloxacin in experimental pneumonia caused by Chlamydia pneumoniae in leukopenic mice. Antimicrob. Agents Chemother. 38:1757-1762.
22. Wolf, K., and R. Malinverni. 1999. Effect of azithromycin plus rifampin versus that of azithromycin alone on the eradication of Chlamydia pneumoniae from lung tissue in experimental pneumonitis. Antimicrob. Agents Chemother. 43:1491-1493.
23. Yang, Z. P., C. C. Kuo, and J. T. Grayston. 1993. A mouse model of Chlamydia pneumoniae strain TWAR pneumonitis. Infect. Immun. 61:2037-2040.